

Are “Sartans” the Common Treatment for COVID-19 and Parkinson’s Disease?

Abstract

COVID-19 disease is caused by the SARS-CoV-2 virus that, after originating in Wuhan, China, spread rapidly throughout the world. As this pathogen enters host cells through the angiotensin converting enzyme 2 protein, angiotensin II hydrolysis may be impaired, contributing to COVID-19 pathology. Indeed, angiotensin II serum levels have been positively correlated with both the SARS-CoV-2 viral load and the severity of lung injuries. Moreover, angiotensin II binding to its type 1 receptors has been associated with host immune dysfunction and the subsequent COVID-19 critical illness. On the other hand, disruption of this signaling pathway in the brain substantia nigra has been associated with Parkinson’s disease, suggesting that SARS-CoV-2 infection may share a common pathophysiology with movement disorders. The connection between COVID-19 and Parkinson’s disease is further supported by the fact that antiviral natural killer cells and cytotoxic T cells express both renin-angiotensin and dopamine systems that the virus can exploit for immune evasion.

In this perspective article, we look at angiotensin II receptor blockers, “sartans”, alone or in combination with angiotensin II (1-7) agonists, as potential treatment modalities for both COVID-19 and Parkinson’s disease.

Keywords: Sartans; COVID-19; Delirium

Introduction

COVID-19 pandemic is caused by the SARS-CoV-2 virus that originated in China and spread rapidly around the globe, infecting, at the time of this writing, over 3 million people and causing more than 300,000 fatalities. It is believed that 40-50% of COVID-19 patients present with neuropsychiatric symptoms, including strokes, cognitive

dysfunction, depression, psychosis and delirium, suggesting that SARS-CoV-2 may be a neurotropic virus [1-4]. Although, Parkinson’s disease (PD) or secondary parkinsonism have not been described in association with COVID-19, movement disorders have accompanied prior pandemics, suggesting that they could follow [5,6].

SARS-CoV-2 enters host cells through the angiotensin converting enzyme 2 (ACE-2), likely impairing angiotensin II (ANG II) hydrolysis into angiotensin [1-7]. This may lead to the unopposed accumulation of ANG II and COVID-19 pathology. Indeed, several studies have associated ANG II serum levels with SARS-CoV-2 viral load and the severity of lung injuries [7-9]. In addition, ANG II activation of its type 1 receptors (AT-1Rs) was found to facilitate viral infection by disabling mitochondria-mediated immunity [10-12].

Aside from the traditional or circulating renin-angiotensin system (RAS), the brain and immune cells express a local RAS, essential for the integrity of antiviral defense and the substantia nigra (SN) dopaminergic neurons [13]. RAS homeostasis is maintained by balancing its two opposing branches, the vertical, with ANG II as its main representative, and the horizontal, comprised of angiotensin [1-7], aldosterone and their receptors [14]. Together these pathways regulate the production of reactive oxygen species (ROS) and nitric oxide (NO), limiting the generation of toxic peroxynitrite [15]. When SARS-CoV-2 binds ACE-2, the horizontal RAS branch may be disabled, and the vertical enhanced, theoretically predisposing to both COVID-19 and parkinsonism (Figure 1). Indeed, the vertical branch inhibitors or angiotensin receptor blockers (ARBs) were found to be beneficial in PD animal models and are currently in clinical trials for COVID-19, suggesting therapeutic properties for both conditions [16-21] (NCT04335123) (NCT04312009) (NCT04311177). According to this model, ARBs combined with horizontal RAS agonists may completely reverse the SARS-CoV-2 immune suppression, ameliorating both the infectious and neuropsychiatric consequences of this virus.

COVID-19 and Angiotensin II


Numerous studies have connected COVID-19 pandemic with RAS and its component, ACE-2. As SARS-CoV-2 virus accesses host tissues via ACE-2 protein, it likely impairs ANG II hydrolysis, leading to the unopposed accumulation of this peptide. In addition, as RAS and ACE-2 are also expressed by the host immune cells, viral binding may disrupt immunity, predisposing to the COVID-19. Moreover, immune cells, including NK cells, also express a dopamine system (DAS) which interacts with RAS at the mitochondrial level, regulating antiviral responses [22,23]. Indeed, several earlier studies have shown that ANG II activation of its type 1 receptors (AT-1Rs) disrupts mitochondrial antiviral signaling (MAVS) proteins and the generation of type I interferon [10,12]. This is further supported by the studies that found a direct relationship between ANG II serum levels, SARS-CoV-2 viral load and the severity of lung injuries, linking this illness to mitochondria-mediated immunity [7-9].

Comment [M14]: Start each sentence from the beginning of the line

Comment [M11]: Re-arrange abstract.

Comment [M12]: Start all sentence from the beginning of the line

Comment [M13]: Give reference



1R signaling, generates ROS which, aside from inducing oxidative

Comment [M15]: Remove square from figure

Aside from regulating the arterial blood pressure, RAS is essential for NO homeostasis, peroxynitrite downregulation and lowering the oxidative and nitrosative stress [24]. Indeed, novel data have indicated that, contrary to prior beliefs, NO is a potent antioxidant, neuroprotector and inhibitor of SARS-CoV-2 replication [25]. However, in the presence of excessive oxidation, NO engenders peroxynitrite, a toxin that promotes both viral infection and SN damage [24,26,27]. Indeed, SARS-CoV-2 virus may facilitate its own replication by generating excessive peroxynitrite and ROS as well as by depleting NO [28,29]. As a result of these findings, not only has the US Food and Drug Administration (FDA) expanded the use of NO in COVID-19 but is currently evaluating it for its overall antiviral properties [30] (NCT04388683).

Aside from the immune cells, RAS and ACE-2 are also expressed by the SN dopaminergic neurons, therefore movement disorders could follow SARS-CoV-2 infection [13]. Indeed, dysfunctional ANG II/AT-1R signaling in SN was reported in PD animal models, revealing the RAS and DAS interconnectedness in this disorder [31]. Along these lines, recent studies have found that excessive SN peroxynitrite impairs dopamine (DA) synthesis, likely contributing to parkinsonism [32-34]. Others have demonstrated a direct relationship between the serum peroxynitrite level and scoring on the unified Parkinson's disease rating scale (UPDRS), linking this disorder to RAS and DAS dysregulation [35,36].

RAS is comprised of two opposing pathways joined by the ANG II/ACE-2 interaction. The vertical branch, consisting of ANG II/AT-

stress, play a major signaling role [37]. The horizontal RAS branch, represented by ANG [1-7], alamandine and their respective receptors MasR and MrgD, generates NO, optimizing antiviral immunity and the homeostasis of SN dopaminergic neurons [38,39]. When SARS-CoV-2 binds ACE-2, the signaling in the vertical RAS branch may be enhanced, while the horizontal is inhibited, favoring both viral infection and movement disorders (Figure 1).

Taken together, COVID-19 disrupts antiviral immunity by upregulating the vertical RAS and inhibiting the protective horizontal branch. This results in increased oxidative and nitrosative stress, peroxynitrite upregulation and lower NO, predisposing to COVID-19 and secondary parkinsonism [28].

Covid-19 and Cellular Senescence

Novel studies have connected the excessive activation of vertical RAS branch with p21-mediated cellular senescence in several tissues, including the brain, endothelia and immunity [40-42]. This is significant as a recent study reported that dopaminergic neurons in PD may not undergo apoptosis, as previously believed, but p21-induced cellular senescence [43,44]. As senescence may be potentially reversible, this is good news for patients with PD providing a safe modality for p21 inhibition.

Many studies have reported that viruses replicate more effectively in senescent cells and can induce this phenotype in host tissues [45-47]. For example, the H7N9 influenza virus triggers endothelial cell senescence to disrupt the blood-brain barrier (BBB) and enter the brain [48]. Other examples of virus-induced cellular senescence include the human immunodeficiency virus (HIV) and cytomegalovirus (CMV) that thrive by promoting host immune senescence [49]. To induce senescence and activate p21, viruses often attack mitochondria, releasing excessive ROS and mitochondrial DNA (mtDNA) [50]. Interestingly, PD was associated with abnormal "immune aging", involving NK cells and CD4 lymphocytes, linking senescence to the pathogenesis of this movement disorder [51-53]. Along these lines, a recent study has found that COVID-19 patients age and die prematurely, losing on average a decade in years of life lost (YLL), linking this virus to aging [54]. Moreover, since COVID-19 appears to target older individuals, this pathogen may promote premature senescence in addition to accelerating the normal aging process [55]. Taken together, this data is in line with prior findings, linking virus-induced senescence to neurodegenerative disorders [45,56,57].

A Fresh Look at Viral Parkinsonism

Viral parkinsonism is a topic closely related to cellular senescence as viruses were demonstrated to induce this phenotype in many cell types, including the neurons and lymphocytes, promoting neurodegeneration [58]. Primary PD is a progressive neurodegenerative disorder marked by motor and non-motor symptoms, caused by an impairment of SN dopaminergic neurons [59]. Secondary parkinsonism or PD-like symptoms can be induced by numerous agents, including viral infections along with the oxidative or nitrosative stress triggered by these pathogens [60-62].

Many viruses, probably including SARS-CoV-2, are neurotropic and capable of inducing SN damage. Indeed, around half of COVID-19 patients were found to experience SARS-CoV-2-related symptoms, including inattention, depression, psychosis and delirium [1-4]. Similar


Comment [M16]: As above

neuropsychiatric manifestations were described following the 1918 influenza pandemic that may have caused encephalitis lethargica (EL), a condition marked by various central nervous system (CNS) symptoms, including movement disorders [63–65]. Contemporary cases of virus-induced EL have been accompanied by secondary parkinsonism, linking viruses to DAS disruption [64]. Interestingly, viruses were demonstrated to lower immune responses by altering host DA levels which in return may induce parkinsonism [23,66]. For example, Japanese encephalitis virus (JEV) was shown to enter host cells via DA receptors and target SN, resulting in movement disorders [67]. Another example is HIV which lowers host immune responses by downregulating human dopamine transporters (hDATs), an action that often triggers parkinsonism [68,69]. The link between DA and immunity is further substantiated by the fact that PD patients treated with L-DOPA or DA agonists frequently develop immune adverse effects [70,71]. Interestingly, peroxynitrate was found to inhibit hDAT, suggesting that SARS-CoV-2 upregulation of this toxin may suppress immunity [72,73]. Indeed, as low hDAT levels characterize PD, COVID-19 peroxynitrate upregulation may lower these proteins further, exacerbating SN damage [74]. On the other hand, DA blockers, including chlorpromazine, have been demonstrated to augment host antiviral immunity and were proposed as COVID-19 treatments [75–77] (NCT04366739). As a result of these findings, we speculate that patients taking antipsychotic medications may be somewhat protected against SARS-CoV-2 infection as suggested by the emerging research on forensic inpatients (unpublished data). Additionally, methamphetamine (METH) use disorder has been associated with both PD and impaired immunity, linking this drug to COVID-19 vulnerability (see the next section).

Are NK Cells the Missing Link between COVID-19 and PD? NK cells are innate immune lymphocytes that play a major role in clearing malignant, virus-infected and senescent cells, preventing their accumulation and disease progression [78]. These lymphocytes, expressing both RAS and DAS, maintain the integrity of both antiviral immunity and the SN dopamineergic neurons [22,40,78,79]. Lately, NK cells have been under intense scrutiny by the research community as their dysfunction was associated with viral infections, cancer and PD [80]. Indeed, it was recently reported that, under normal circumstances, NK cells slow the progression of PD by clearing α -synuclein [81]. Others have reported a direct relationship between α -synuclein and hDAT in NK cells and SN, emphasizing the role of these transporters in antiviral immunity and the SN integrity [82]. As hDATs regulate extra- and intracellular DA levels, viral exploitation of these proteins may lower immune responses and predispose to PD. Indeed, as human NK cells express higher levels of DA receptors compared to other immune cells, they are more susceptible to viral manipulation [23]. Indeed, earlier studies have reported that upregulated DA inhibits NK cell function via the immune checkpoint, NKG2A [79]. A recent study found that SARS-CoV-2 can disrupt NK cells by upregulating NKG2A [83]. For this reason, active NK cells are recurrently in clinical trials for COVID-19 (NCT04324996) (NCT04375176). Furthermore, as under normal circumstances, NK cells also function to eliminate senescent cells, they may directly link PD to 21-induced cellular senescence [10,43]. Indeed, it has been reported that senescent cells overexpressing NKG2A immune checkpoint are resistant to NK cell elimination, associating once more viruses with senescence [83,84]. The NK cells RAS and DAS and their link to antiviral immunity and PD is further supported by methamphetamine (METH) studies.

Several reports have been published, linking chronic METH exposure to lower NK cells number and function, suggesting that users may be at higher risk of both PD and COVID-19 illness [85–89]. Indeed, METH-upregulated peroxynitrate and hDAT downregulation were reported to exacerbate movement disorders [87,88]. Interestingly, like COVID-19, METH was demonstrated to augment ANG II/AT-1R signaling, linking DA to vertical RAS activation [90]. Moreover, preclinical studies have reported that candesartan treatment decreases METH self-administration, linking RAS and DAS and indicating that this ARB may be a drug of choice for COVID-19 METH users [91]. Furthermore, aside from directly inhibiting hDAT, METH may promote PD indirectly by disrupting the function of NK cells leading to α -synuclein accumulation [92–95].

Several studies have connected METH with mitochondrial disruption and susceptibility to COVID-19, suggesting once more the centrality of these organelles in antiviral immunity [96–98]. Indeed, under normal circumstances, viral RNA activates mitochondrial MAVS (via RIG-1), inducing the synthesis of type 1 interferon to eliminate the virus (Figure 2) [99]. With the same token, α -synuclein accumulation may predispose to COVID-19 by impairing NK cells [100].



Taken together, this data suggests that ARBs may benefit both COVID-19 and PD patients as these agents may augment immunity and protect SN. Moreover, adding ANG [1–7] agonists may optimize the antiviral and PD treatment by reactivating the horizontal RAS branch.

Comment [M17]: Remove square from figure

Conclusion

Severe illness and neuropsychiatric manifestations associated with COVID-19 may have a common denominator: Over activation of the vertical RAS branch and blocking the horizontal. Excess generation of ANG II and peroxynitrite likely disrupts the RAS and DAS in both NK cells and SN, damaging antiviral immunity and the dopaminergic neurons.

This model predicts both, that movement sequelae may follow COVID-19 and that "sartans", alone or in combination with ANG [1-7] agonists, could be therapeutic for both.

References

1. Mao L, Wang M, Chen S (2020) Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. *JAMA Neurol* 77:683-690.
2. Jin H, Hong C, Chen S, Zhou Y, Wang Y, et al. (2020) Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. *Stroke and Vascular Neurology* 5:146-151.
3. Varatharaj A, Thomas N, Ellul M, Davies NWS, Pollak T, et al. (2020) UK-wide surveillance of neurological and neuropsychiatric complications of COVID-19: The first 153 patients. *The Lancet Psychiatry* 7:875-882.
4. Rogers JP, Chesney E, Oliver D, Pollak AP, McGuire PP, et al. (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 7:611-627.
5. Troyer EA, Kohn JN, Hong S (2020) Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. *Brain Behav Immun* 87:34-39.
6. Tipton PW, Wszolek ZK (2020) What can Parkinson's disease teach us about COVID-19? *Neurology* 94:204-206.
7. Liu Y, Yang Y, Zhang C, Huang F, Wang F, et al. (2020) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* 63:364-374.
8. Reddy R, Asante I, Liu S, Parikh P, Liebler J, et al. (2019) Circulating angiotensin peptide levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study. *PLoS ONE* 14:e0213096.
9. Kuba K, Imai Y, Rao S, Gao H, Guo F, et al. (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 11:875-879.
10. Song P, Kim JH (2019) Benefits of Angiotensin Receptor Blockade: Preventing Smooth Muscle Cell Senescence and Beyond. *Korean Circ J* 49:627-628.
11. Saavedra JM (2020) Angiotensin receptor blockers and COVID-19. *Pharmacol Res* 156:104832.
12. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, et al. (2017) A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit Care* 21:234.
13. Angajala A, Lim S, Phillips JB, Kim JH, Yates C, et al. (2018) Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism. *Front Immunol* 9:1605.
14. Schleifenbaum J (2019) Almandine and Its Receptor MrgD Pair Up

to Join the Protective Arm of the Renin-Angiotensin System. *Front Med (Lausanne)* 6:107.

Comment [M18]: Strictly follow the referencing style of the journal

Comment [M19]: Update your references within the last five years

15. Dibo P, Marañón RO, Chandrashekar K, Mazzuferi F, Silva GB, et al.(2019) Angiotensin-(1-7) inhibits sodium transport via Mas receptor by increasing nitric oxide production in thick ascending limb. *Physiol Rep* 7: e14015.
16. Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, et al. (2014) Antihypertensive agents and risk of Parkinson's disease: A nationwide cohort study. *PLoS One* 9:e98961.
17. Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F (2017) Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease. *Expert Opin Investig Drugs* 26:1163-1173.
18. Rodríguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, et al. (2007) Mechanism of 6-hydroxydopamine neurotoxicity: The role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. *J Neurochem* 103:145-156.
19. Mertens B, Varcin M, Michotte Y, Sarre S (2011) The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death. *European Journal of Neuroscience* 34:1141-1148.
20. Villapol S, Saavedra JM (2015) Neuroprotective effects of angiotensin receptor blockers. *Am J Hypertens* 28:289-299.
21. Reardon KA, Mendelsohn FA, Chai SY, Horne MK (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. *Aust N Z J Med* 30:48-53.
22. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, et al. (2007) Human T and natural killer cells possess a functional renin-angiotensin system: Further mechanisms of angiotensin II-induced inflammation. *J Am Soc Nephrol* 18: 1093-1102.
23. Arreola R, Alvarez-Herrera S, Pérez-Sánchez G, Villanueva EB, Cruz-Fuentes C, et al. (2016) Immunomodulatory Effects Mediated by Dopamine. *J Immunol Res* 2016: 3160486.
24. Hummel SG, Fischer AJ, Martin SM, Schafer FQ, Buettner GR (2006) Nitric oxide as a cellular antioxidant: A little goes a long way. *Free Radic Biol Med* 40: 501-506.
25. Åkerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist A, et al. (2005) Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. *J Virol* 79:1966-1969.
26. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 87: 315-424.
27. Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, et al. (2002) Nitric oxide: An antioxidant and neuroprotector. *Ann NY Acad Sci* 962: 389-401.
28. Green SJ (2020) Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. *Microbes Infect* 22:149-150.
29. Delgado-Roche L, Mesta F (2020) Oxidative Stress as a Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) infection. *Arch Med Res* 51: 384-387.
30. Kobayashi J, Murata I (2020) Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. *Ann Intensive Care* 10: 61.
31. Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F (2017) Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease. *Expert Opin Investig Drugs* 26:1163-1173.
32. Park SU, Ferrer JV, Javitch JA, Kuhn DM (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: Potential mechanism of neurotoxicity in dopamine neurons. *J Neurosci* 22: 4399-4405.

33. Ara J, Przedborski S, Naini AB, Lewis VJ, Trifelti RR, et al. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *Proc Natl Acad Sci USA* 95: 7659-7663.
34. Szabó C, Ischiropoulos H, Radi R (2007) Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. *Nat Rev Drug Discov* 6: 662-680.
35. Girouard H, Park L, Anrather J, Zhou P, Iadecola C (2007) Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. *Arterioscler Thromb Vasc Biol* 27:303-309.
36. Kouti L, Noroozian M, Akhondzadeh S, Abdollahi M, Javadi MR, et al. (2013) Nitric oxide and peroxynitrite serum levels in Parkinson's disease: Correlation of oxidative stress and the severity of the disease. *Eur Rev Med Pharmacol Sci* 17: 964-970.
37. Welch WJ (2008) Angiotensin II-dependent superoxide: Effects on hypertension and vascular dysfunction. *Hypertension* 52: 51-56.
38. Rabie MA, Abdel Fattah MA, Nassar NN, El-Abhar HS, Abdallah DM (2018) Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF- κ B axis. *Biochem Pharmacol* 151: 126-134.
39. Wright JW, Kawas LH, Harding JW (2013) A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases. *Front Endocrinol (Lausanne)* 4: 158.
40. Labandeira-García JL, Garrido-Gil P, Rodríguez-Pallares J, Valenzuela R, Borrajo A, et al. (2014) Brain renin-angiotensin system and dopaminergic cell vulnerability. *Front Neuroanat* 8: 67.
41. Haynes LD, Verma S, McDonald B, Wu R, Tacke R, et al. (2015) Cardif (MAVS) Regulates the Maturation of NK Cells. *J Immunol* 195: 2157-2167.
42. Martín-Ruiz C, Williams-Gray CH, Yarnall AJ, Boucher JJ, Lawson RA, et al. (2020) Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. *J Parkinsons Dis* 10: 193-206.
43. Riessland M, Kolisnyk B, Kim TW, Cheng J, Nij, et al. (2019) Loss of SATB1 Induces p21-Dependent Cellular Senescence in Postmitotic Dopaminergic Neurons. *Cell Stem Cell* 25: 514-530.e8.
44. Im JH, Yeo IJ, Jeon SH, Lee DH, Ham HJ, et al. (2020). p21 inhibitor UC2288 ameliorates MPTP induced Parkinson's disease progression through inhibition of oxidative stress and neuroinflammation. *European PMC*.
45. Kim JA, Seong RK, Shin OS (2016) Enhanced Viral Replication by Cellular Replicative Senescence. *Immune Netw* 16: 286-295.
46. Chuprin A, Gal H, Biron-Shental T, Biran A, Amiel A, et al. (2017) Cell fusion induced by ERVWE1 or measles virus causes cellular senescence. *Genes Dev* 27: 2356-2366.
47. Kritsilis M, VRizou S, Koutsoudaki PN, Evangelou K, Gorgoulis VG, et al. (2018) Ageing, Cellular Senescence and Neurodegenerative Disease. *Int J Mol Sci* 19: 2937.
48. Yan Y, Du Y, Zheng H, Wang G, Li R, et al. (2017) NS1 of H7N9 Influenza A Virus Induces NO-Mediated Cellular Senescence in Neuro2a Cells. *Cell Physiol Biochem* 43: 1369-1380.
49. Combs JA, Norton EB, Saifudeen ZR, Bentrup KHJ, Katakam PV, et al. (2020) Human Cytomegalovirus Alters Host Cell Mitochondrial Function during Acute Infection. *J Virol* 94:e01183-19.
50. Passos JF, Nelson G, Wang C, Richter T, Simillion C, et al. (2010) Feed-back between p21 and reactive oxygen production is necessary for cell senescence. *Mol Syst Biol* 6: 347.
51. Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, et al. (2018) Abnormalities of age-related T cell senescence in Parkinson's disease. *J Neuroinflammation* 15: 166.
52. Costantini E, D'Angelo C, Reale M (2018) The Role of Immunosenescence in Neurodegenerative Diseases. *Mediators Inflamm* 2018: 6039171.
53. Tansey MG, Romero-Ramos M (2019) Immune system responses in Parkinson's disease: Early and dynamic. *Eur J Neurosci* 49: 364-383.
54. Hanlon P, Chadwick F, Shah A, Wood R, Minton J, et al. (2020) COVID-19: exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: A modelling study. *Wellcome Open Res* 5: 75.
55. Sargiacomo C, Sotgia F, Lisanti MP (2020) COVID-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of coronavirus infection? *Aging (Albany NY)* 12: 6511-6517.
56. Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F (2020) Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats. *Cells* 9: 909.
57. Delgado-Roche L, Mesta F (2020) Oxidative Stress as a Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. *Arch Med Res* 51: 384-387.
58. Zhou L, Miranda-Saksena M, Saksena NK (2013) Viruses and neurodegeneration. *Virol J* 10: 172.
59. DeMaagd G, Philip A (2020) Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. *PT* 40: 504-532.
60. Colosimo C, Morgante L, Antonini A, Barone P, Avarello TP, et al. (2010) Non-motor symptoms in atypical and secondary parkinsonism: The PRIAMO study. *J Neurol* 257: 5-14.
61. Lee C (2018) Therapeutic Modulation of Virus-Induced Oxidative Stress via the Nrf2-Dependent Antioxidative Pathway. *Oxid Med Cell Longev* 2018: 6208067.
62. Castro R, Pinzón HS, Alvis-Guzman N (2015) A systematic review of observational studies on oxidative/nitrosative stress involvement in dengue pathogenesis. *Colomb Med (Cali)* 46: 135-143.
63. Jang H, Boltz DA, Webster RG, Smeyne RJ (2009) Viral parkinsonism. *Biochim Biophys Acta* 1792: 714-721.
64. Dale RC, Webster R, Gill D (2007) Contemporary encephalitis lethargica presenting with agitated catatonia, stereotypy, and dystonia-parkinsonism. *Mov Disord* 22: 2281-2284.
65. Von Economo C (1931) In: *Encephalitis Lethargica: Its Sequelae and Treatment*. Newmark O, translator. London: Oxford University Press.
66. Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E (1999) Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF- κ B in cells of the immune system. *Nucleic Acids Res* 27: 3291-3299.
67. Simanjuntak Y, Liang JJ, Lee YL, Lin YL (2017) Japanese Encephalitis Virus Exploits Dopamine D2 Receptor-phospholipase C to Target Dopaminergic Human Neuronal Cells. *Front Microbiol* 8: 651.
68. Cardoso F (2002) HIV-related movement disorders: Epidemiology, pathogenesis and management. *CNS Drugs* 16: 663-668.
69. Zhu J, Ananthan S, Zhan CG (2018) The role of human dopamine transporter in NeuroAIDS. *Pharmacol Ther* 183: 78-89.
70. Lieberknecht V, Junqueira SC, Cunha MP, Barbosa TA, de Souza LF, et al. (2017) Pramipexole, a Dopamine D2/D3 receptor-preferring agonist, prevents experimental autoimmune encephalomyelitis

UNDER PEER REVIEW

71. Breger LS, Kienle K, Smith GA, Dunnett SB, Lane EL (2017) Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease. *Brain Behav Immun* 2017: 155-164.
72. Park S, Geddes TJ, Javitch JA, Kuhn DM (2003) Dopamine prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide: Is nitrotyrosine formation a nearly step in dopamine neuronal damage? *J Biol Chem* 278: 28736-28742.
73. Park SU, Ferrer JV, Javitch JA, Kuhn DM (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: Potential mechanism of neurotoxicity in dopamine neurons. *J Neurosci* 22: 4399-4405.
74. Mackie P, Lebowitz J, Saadatpour L, Nickloff E, Gaskill P, et al. (2018) The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease. *Brain Behav Immun* 70: 21-35.
75. Bhattacharyya S, Warfield KL, Ruthel G, Bavari S, Aman MJ, et al. (2010) Ebola virus uses clathrin-mediated endocytosis as an entry pathway. *Virology* 401: 18-28.
76. Plaze M, Attali D, Petit AC, et al. (2020) Repositionnement de la chlorpromazine dans le traitement du COVID-19: Etude de recovery. *Encephale* 46: S35-S39.
77. Smith JL, Stein DA, Shum D, Fischer MA, Radu C, et al. (2014) Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. *J Virol* 88: 5533-5542.
78. Antonangeli F, Zingoni A, Soriani A, Santoni A (2019) Senescent cells: Living or dying is a matter of NK cells. *J Leukoc Biol* 105: 1275-1283.
79. Mikulak J, Bozzo L, Roberto A, Pontarini E, Tentorio P, et al. (2014) Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. *J Immunol* 193: 2792-2800.
80. Niwa F, Kuriyama N, Nakagawa M, Imanishi J (2012) Effect of peripherallymphocytesubpopulations and the clinical correlation with Parkinson's disease. *Geriatr Gerontol Int* 12: 102-107.
81. Earls RH, Menees KB, Chung J, Gutekunst C, Lee HJ, et al. (2020) NK cells clear α -synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α -synucleinopathy. *Proc Natl Acad Sci USA* 117: 1762-1771.
82. Butler B, Saha K, Rana T, Becker JP, Sambo D, et al. (2015) Dopamine Transporter Activity Is Modulated by α -Synuclein. *J Biol Chem* 290: 29542-29554.
83. Yaqinuddin A, Kashir J (2020) Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholorquine, and antiviral agents. *Med Hypotheses* 140: 109777.
84. Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers CS, Subramanian P, et al. (2019) Senescent cells evade immune clearance via HLA-E-mediated NK and CD8⁺ T cell inhibition. *Nat Commun* 10: 2387.
85. Lappin JM, Darke S, Farrell M (2018) Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. *Drug Alcohol Depend* 187: 134-140.
86. Volkow ND (2020) Collision of the COVID-19 and Addiction. *Ann Intern Med* 173: 61-62.
87. Imam SZ, Crow JP, Newport GD, Islam F, Slikker W, et al. (1999) Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: Protective effects of peroxynitrite decomposition catalyst. *Brain Res* 837: 15-21.
88. Martel J, Ko YF, Young JD, Ojcius DM (2020) Could nasal nitric oxide help to mitigate the severity of COVID-19? *Microbes Infect* 22: 168-171.
89. Harms R, Morsey B, Boyer CW, Fox HS, Sarvetnick N (2012) Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression. *PLoS One* 7: e49897.
90. Marchese NA, Artur de la Villarmois E, Basmaadjian OM, Perez MF, Baiardi G, et al. (2016) Brain Angiotensin II AT1 receptors are involved in the acute and long-term amphetamine-induced neurocognitive alterations. *Psychopharmacology (Berl)* 233: 795-807.
91. Xu X, Pan J, Li X, Cui Y, Mao Z, et al. (2019) Inhibition of Methamphetamine Self-Administration and Reinstatement by Central Blockade of Angiotensin II Receptor in Rats. *J Pharmacol Exp Ther* 369: 244-258.
92. Potula R, Haldar B, Cenna JM, Sriram U, Fan S (2018) Methamphetamine alters T cell cycle entry and progression: Role in immune dysfunction. *Cell Death Discovery* 4: 44.
93. Sriram U, Haldar B, Cenna JM, Gofman L, Potula R (2015) Methamphetamine mediates immunodysregulation in a murine model of chronic viral infection. *Front Microbiol* 6: 793.
94. Jiang L, Zhu R, Bu Q, Li Y, Shao X, et al. (2018) Brain Renin-Angiotensin System Blockade Attenuates Methamphetamine-Induced Hyperlocomotion and Neurotoxicity. *Neurotherapeutics* 15: 500-510.
95. Callaghan RC, Cunningham JK, Sykes S, Kish SJ (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. *Drug Alcohol Dependence* 120: 35-40.
96. Liu XL, Wang YD, Yu XM, Li DW, Li GR (2018) Mitochondria-mediated damage to dopaminergic neurons in Parkinson's disease (Review). *Int J Mol Med* 41: 615-623.
97. Doughan AK, Harrison DG, Dikalov SI (2008) Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: Linking mitochondrial oxidative damage and vascular endothelial dysfunction. *Circ Res* 102: 488-496.
98. Koshiba T, Bashiruddin N, Kawabata S (2011) Mitochondria and antiviral innate immunity. *Int J Biochem Mol Biol* 2: 257-262.
99. Wu W, Wang X, Zhang W (2018) RIG-I Signaling via MAVS Is Dispensable for Survival in Lethal Influenza Infection In Vivo. *Mediators Inflamm* 2018: 6808934.
100. Ganjam GK, Bolte K, Matschke LA, Neitemeier S, Dolgaet AM, et al. (2019) Mitochondrial damage by α -synuclein causes cell death in human and dopaminergic neurons. *Cell Death Dis* 10: 865.

Advances In Industrial Biotechnology | ISSN: 2639-5665
Advances In Microbiology Research | ISSN: 2689-694X
Archives Of Surgery And Surgical Education | ISSN: 2689-3126
Archives Of Urology | ISSN: 2640-7779
Current Trends Medical And Biological Engineering | ISSN: 2689-310X
International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X
Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276
Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292
Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370
Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594
Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X
Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562
Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608
Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879
Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397
Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751
Journal Of Aquaculture & Fisheries | ISSN: 2576-5523
Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780
Journal Of Biotech Research & Biochemistry | ISSN: 2639-010X
Journal Of Brain & Neuroscience Research | ISSN: 2470-7546
Journal Of Cardiology Study & Research | ISSN: 2640-768X
Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943
Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771
Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844
Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801
Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978
Journal Of Cytology & Tissue Biology | ISSN: 2378-9107
Journal Of Dairy Research & Technology | ISSN: 2688-9315
Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783
Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X
Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798
Journal Of Environmental Science Current Research | ISSN: 2643-5020
Journal Of Food Science & Nutrition | ISSN: 2470-1076
Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X
Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566

Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485
Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662
Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999
Journal Of Hospice & Palliative Medical Care | ISSN: 2572-9640
Journal Of Human Endocrinology | ISSN: 2572-9640
Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654
Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493
Journal Of Light & Laser Current Trends | ISSN: 2639-5657
Journal Of Modern Chemical Sciences | ISSN: 2381-2044
Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X
Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313
Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400
Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419
Journal Of Obesity & Weight Loss | ISSN: 2473-7372
Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887
Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052
Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X
Journal Of Pathology Clinical & Medical Research | ISSN: 2639-5649
Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670
Journal Of Plant Science Current Research | ISSN: 2639-3743
Journal Of Practical & Professional Nursing | ISSN: 2639-5681
Journal Of Protein Research & Bioinformatics | ISSN: 2573-0150
Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150
Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177
Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574
Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060
Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284
Journal Of Toxicology Current Research | ISSN: 2639-3735
Journal Of Translational Science And Research | ISSN: 2573-0193
Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193
Journal Of Virology & Antivirals | ISSN: 2689-8829
Trends In Anatomy & Physiology | ISSN: 2640-7752